middl
eastern
man
longstand
axspa
adalimumab
present
sever
day
persist
fever
axspa
diagnos
basi
histori
recurr
iriti
patellar
tendon
enthes
inflammatori
lower
back
pain
back
pain
although
initi
respons
becam
refractori
nonsteroid
antiinflammatori
medic
sacroiliac
joint
steroid
inject
adalimumab
start
april
next
month
dramat
improv
inflammatori
back
pain
extraarticular
manifest
june
present
hospit
endors
day
high
fever
mild
lower
chest
discomfort
cough
describ
unremit
fever
occur
multipl
time
daili
associ
signific
weak
rigor
review
system
otherwis
neg
pertin
past
medic
histori
medic
famili
histori
noncontributori
social
histori
notabl
move
usa
saudi
arabia
year
ago
recent
frequent
travel
around
usa
mexico
travel
la
vega
work
confer
day
prior
present
admiss
temperatur
blood
pressur
mmhg
puls
beat
per
minut
illappear
physic
exam
otherwis
notabl
splenomegali
tender
palpat
initi
lab
reveal
lymphopenia
absolut
lymphocyt
count
mild
anemia
hemoglobin
gdl
thrombocytopenia
transamin
ast
ul
alt
ul
erythrocyt
sediment
rate
esr
mmh
creactiv
protein
crp
mgdl
extens
infecti
diseas
workup
undertaken
test
report
neg
tabl
comput
tomographi
ct
chest
abdomen
pelvi
show
mild
splenomegali
residu
thymic
tissu
lymphadenopathi
week
hospit
patient
remain
febril
despit
treatment
antipyret
develop
transient
faint
erythemat
maculopapular
rash
trunk
lab
demonstr
elev
ferritin
mgdl
fibrinogen
mgdl
triglycerid
mgdl
crp
peak
mgdl
diagnosi
ma
consid
seventh
day
hospit
start
anakinra
mg
twice
daili
without
adequ
fever
control
thu
oral
prednison
mg
daili
ad
quickli
defervesc
improv
condit
lab
inflammatori
marker
fig
bone
marrow
biopsi
obtain
hospit
day
show
erythroid
hyperplasia
hemophagocyt
histiocyt
without
evid
malign
fig
solubl
receptor
level
howev
low
hospit
discharg
prednison
mg
daili
anakinra
mg
daili
adalimumab
complet
discontinu
upon
outpati
followup
continu
symptomat
improv
normal
esr
crp
ferritin
fibrinogen
taper
prednison
month
inflammatori
back
pain
return
ma
potenti
fatal
syndrom
present
patient
inflammatori
condit
consid
similar
hemophagocyt
lymphohistiocytosi
hlh
find
abund
activ
hemophagocyt
macrophag
histiocyt
led
classif
histiocyt
disord
underli
pathogenesi
ma
poorli
understood
propos
trigger
incit
event
infect
malign
autoimmun
condit
drug
lead
immun
dysregul
result
overwhelm
cytokin
storm
drive
phagocytosi
blood
cell
precursor
infiltr
macrophag
tissu
caus
multiorgan
dysfunct
current
diagnost
criteria
ma
adult
propos
classif
criteria
reli
understand
pediatr
popul
find
high
fever
cytopenia
hyperferritinemia
hypertriglyceridemia
alert
clinician
possibl
ma
although
significantli
elev
ferritin
specif
hlh
pediatr
specif
hlh
ma
adult
popul
evid
hemophagocyt
cell
bone
marrow
biopsi
requir
diagnosi
alway
found
present
ma
consist
diagnosi
patient
ma
high
persist
fever
without
infecti
caus
lymphopenia
anemia
mark
hyperferritinemia
hypertriglyceridemia
splenomegali
presenc
hemophagocyt
bone
marrow
biopsi
diagnosi
adultonset
still
diseas
aosd
exclud
due
axspa
lead
explan
ma
adalimumab
undetect
viral
infect
underli
axspa
infect
particularli
viral
common
report
caus
ma
cite
literatur
patient
extens
infecti
workup
neg
howev
ma
may
trigger
undetect
viru
rheumatolog
condit
ma
associ
underli
activ
system
juvenil
idiopath
arthriti
aosd
rare
case
system
lupu
erythematosu
spa
rare
associ
ma
three
found
review
literatur
tabl
three
case
one
occur
absenc
tnf
inhibitor
use
clear
sourc
infect
patient
wellcontrol
spa
stabl
prior
present
therefor
felt
spa
less
like
trigger
ma
recent
ma
report
frequent
associ
tnf
inhibitor
use
although
unclear
whether
due
heighten
clinician
awar
increas
incid
literatur
review
found
report
ma
associ
etanercept
infliximab
adalimumab
tabl
two
case
describ
time
ma
rel
tnf
inhibitor
administr
one
patient
ra
month
discontinu
etanercept
one
aosd
month
initi
adalimumab
four
case
report
associ
infect
includ
viscer
leishmaniasi
dissemin
histoplasmosi
liver
abscess
primari
ebv
felt
primari
trigger
ma
though
tnf
inhibitor
implic
contribut
risk
factor
infect
plausibl
adalimumab
trigger
ma
patient
present
month
initi
adalimumab
consist
timelin
case
report
obviou
infect
pathogenesi
ma
secondari
tnf
inhibitor
unknown
medic
success
treat
refractori
case
ma
use
may
also
rare
induc
aggrav
autoimmun
diseas
trigger
ma
set
infect
propos
tnf
inhibitor
blockad
macrophag
activ
coupl
compensatori
immun
system
activ
rebound
cytokin
respons
lead
overal
immun
system
dysregul
may
trigger
hemophagocytosi
explan
paradox
effect
immun
respons
requir
research
treatment
ma
note
ma
associ
tnf
inhibitor
six
eight
patient
clinic
laboratori
improv
treatment
highdos
corticosteroid
two
patient
die
despit
receiv
highdos
corticosteroid
howev
patient
present
sever
late
system
diseas
previous
well
control
prednison
case
ma
associ
infect
three
four
patient
receiv
highdos
corticosteroid
addit
treatment
underli
infect
four
patient
respond
well
surviv
three
report
case
ma
spa
three
patient
receiv
highdos
prednison
clinic
stabil
dual
treatment
highdos
steroid
anakinra
receptor
antagonist
induc
remiss
patient
agent
shown
rapidli
induc
remiss
amelior
cytokin
storm
refractori
sever
case
ma
anakinra
trial
first
patient
given
prolong
high
fever
given
durat
symptom
like
presenc
cytokin
besid
alon
suffici
induc
remiss
conclus
import
recogn
ma
possibl
lifethreaten
complic
autoimmun
inflammatori
diseas
current
diagnosi
ma
reli
heavili
pediatr
diagnost
criteria
treatment
case
report
case
seri
adult
import
increas
awar
rare
diseas
among
clinician
order
prevent
mortal
improv
outcom
patient
